We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

78 hedge funds and large institutions have $460M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 19

11% less funds holding

Funds holding: 8878 (-10)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

40% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 25

44% less capital invested

Capital invested by funds: $822M → $460M (-$363M)

Holders
78
Holders Change
-10
Holders Change %
-11.36%
% of All Funds
1.74%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
15
Increased
31
Reduced
19
Closed
25
Calls
$243K
Puts
Net Calls
+$243K
Net Calls Change
-$109K
Name Holding Trade Value Shares
Change
Change in
Stake
PRC
76
Pearl River Capital
Michigan
$3K +$3.22K +131 New
PHK
77
Point72 Hong Kong
Hong Kong
$1K +$639 +26 New
BNP Paribas Financial Markets
78
BNP Paribas Financial Markets
France
$63 -$6.34K -258 -99%
PC
79
Polar Capital
United Kingdom
-$31.2M -805,004 Closed
Viking Global Investors
80
Viking Global Investors
Connecticut
-$28.5M -735,898 Closed
VC
81
Vivo Capital
California
-$8.23M -212,648 Closed
EI
82
EAM Investors
California
-$3.12M -80,580 Closed
IBT
83
International Biotechnology Trust
United Kingdom
-$2.29M -77,000 Closed
Invesco
84
Invesco
Georgia
-$1.75M -45,174 Closed
Federated Hermes
85
Federated Hermes
Pennsylvania
-$1.11M -28,756 Closed
EGI
86
EAM Global Investors
California
-$1.09M -28,089 Closed
Ameriprise
87
Ameriprise
Minnesota
-$961K -24,807 Closed
HI
88
HBK Investments
Texas
-$556K -14,356 Closed
ARTA
89
A.R.T. Advisors
New York
-$451K -11,671 Closed
LCM
90
Laurion Capital Management
New York
-$435K -11,228 Closed
BCM
91
BlueCrest Capital Management
Jersey
-$310K -8,000 Closed
Stifel Financial
92
Stifel Financial
Missouri
-$310K -8,000 Closed
State of Wisconsin Investment Board
93
State of Wisconsin Investment Board
Wisconsin
-$306K -7,900 Closed
KAM
94
Kazazian Asset Management
Florida
-$271K -7,000 Closed
ECM
95
Element Capital Management
New York
-$250K -6,454 Closed
MIM
96
MetLife Investment Management
New Jersey
-$152K -3,916 Closed
MLICM
97
Metropolitan Life Insurance Company (MetLife)
New York
-$107K -2,766 Closed
Pacer Advisors
98
Pacer Advisors
Pennsylvania
-$60K -1,544 Closed
Group One Trading
99
Group One Trading
Illinois
-$35K -900 Closed
FIA
100
FNY Investment Advisers
New York
-$19K -500 Closed

DCPH Hedge Fund Activity: Q4 2018 in Review

78 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q4 2018, worth a combined $460M — down 44% from $822M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of DCPH and 15 opened new positions — a net loss of 10 holders — while 19 trimmed existing stakes and 31 added.

The largest buyer was Millennium Management, adding an estimated $28.6M. The largest seller was Polar Capital, exiting entirely with an estimated $31.2M sold.

  • 78 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q4 2018, down from 88 in Q3 2018.
  • Funds reported $460M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q4 2018, down 44% quarter-over-quarter.
  • 15 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q4 2018 and 25 closed out, a net change of -10 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q4 2018 was Millennium Management, an estimated $28.6M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q4 2018 was Polar Capital, an estimated $31.2M sold.

Based on aggregated 13F filings for Q4 2018.